drug
naldemedine tosylate
Marketedupdated 5mo agoby BioDelivery Sciences International Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 24, 2031
~4.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- May 13, 2033compositionUS 10952968
- May 13, 2033formulationUS 12350377
- Nov 11, 2031compositionUS 9108975
- Feb 24, 2031compositionUS RE463654.4y
- Oct 5, 2026compositionUS RE46375
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that